fullscreen

eFinder

eFinder

Home › Article

Pharma stock soars 150% on injectables deal with Wegovy maker Novo

Cnbc · · 295 words · By Mike Sheen
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Pharma stock soars 150% on injectables deal with Wegovy maker Novo

Shares in Swedish microcap stock Nanexa more than doubled early Friday after the drug-delivery group revealed a $1.33 billion licensing deal with pharma giant Novo Nordisk.

Claims checked 12
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left14%
Center72%
Right14%

7 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Shares in Swedish microcap stock Nanexa more than doubled early Friday after the drug-delivery group revealed a $1.33 billion licensing deal with pharma giant Novo Nordisk.

Why it matters

Nanexa, which trades on the Nasdaq First North Growth Market in Stockholm, said after the closing bell on Thursday it had penned a global licensing agreement covering Novo's long-acting injectable drugs for obesity, type 2 diabetes and other cardiometabolic…

Common ground

Its shares soared more than 150% at the open in Stockholm before settling back to a gain of around 114% by 11:50 a.m.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.cnbc.com/2026/09/25/wegovy-novo-nordisk-obesity-drugs.html

fact_checkClaims Checked

eFinder analyzed this article and checked 12 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 7
schedule Pending 2
verified Verified 2
info Single Source 1
check_circle
Claim 1: “Shares in Swedish microcap stock Nanexa more than doubled early Friday after the drug-delivery group revealed a $1.33 billion licensing deal with pharma giant Novo Nordisk.”
CORROBORATED
Multiple independent sources, including Reuters and other web reports, confirm that Nanexa shares more than doubled following a licensing deal with Novo Nordisk valued at approximately $1.33 billion (€1.17 billion).
travel_explore
web search NEUTRAL — Nanexa shares more than doubled after signing a $1.33 billion Novo Nordisk licensing deal for long-acting obesity and diabetes drug-delivery technology.
https://www.dailymotion.com/video/xbd1t5a
travel_explore
web search NEUTRAL — Shares in Swedish microcap stock Nanexa more than doubled early Friday after the drug-delivery group revealed a $1.33 billion licensing deal with pharma giant Novo Nordisk.
https://www.linkedin.com/news/story/novo-inks-13b-deal-for-m…
travel_explore
web search NEUTRAL — Sept 25 (Reuters) - Shares in Swedish drug-delivery company Nanexa more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk worth up to about €1.…
https://live.euronext.com/en/financial-news/nanexa-shares-so…
schedule
Claim 2: “David Westburg, Nanexa CEO”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
check_circle
Claim 3: “Nanexa is eligible to receive an upfront payment worth around $700 million and potential milestone payments for development and regulatory achievements.”
CORROBORATED
Multiple sources mention an upfront payment of approximately $700 million (or €615 million including milestones) and further milestone payments.
travel_explore
web search NEUTRAL — Sep 25, 2026 · Nanexa will receive an upfront payment of approximately $700 million, plus milestone payments and low single-digit royalties on future product sales. The agreement marks a transformativ…
https://finance.biggo.com/news/90688ef1-2c45-4eb1-b480-912d8…
travel_explore
web search NEUTRAL — Sep 25, 2026 · Nanexa is eligible for an upfront payment of approximately $700 million, milestone payments for development and regulatory achievements, and low single-digit royalties on future product…
https://www.vibetrader.com/news/254f2f62-c851-4209-bd93-0aab…
travel_explore
web search NEUTRAL — Sep 25, 2026 · Nanexa is eligible to receive total payments of up to EUR 1.165 billion, including EUR 615 million in upfront payment and development and regulatory milestones.
https://www.morningstar.com/news/pr-newswire/20260925ln56898…
verified
Claim 4: “Nanexa, which trades on the Nasdaq First North Growth Market in Stockholm”
VERIFIED
Official listing information from Nasdaq Stockholm confirms that Nanexa AB is admitted to trading on the First North Growth Market.
travel_explore
web search NEUTRAL — May 27, 2020 · On request of Nanexa AB, company registration number 556833-0285, Nasdaq Stockholm AB has admitted the company’s shares and equity rights to trading on First North Growth Market...
https://www.nasdaq.com/press-release/listing-of-nanexa-ab-on…
travel_explore
web search NEUTRAL — Get the latest Nanexa AB (publ) (STO:NANEXA) stock price quote with financials, statistics, dividends, charts, historical data and more. Nanexa AB is a Sweden-based company engaged in the drug deliver…
https://stockanalysis.com/quote/sto/NANEXA/
travel_explore
web search NEUTRAL — Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science.
https://www.marketscreener.com/quote/stock/NANEXA-AB-1076345…
info
Claim 5: “The group reported full-year revenues of approximately $3.89 million for 2025, representing a 48.4% increase on the previous year.”
SINGLE SOURCE
The claim regarding 2025 revenues of $3.89 million (a 48.4% increase) appears in one of the web search results for claim 7, but is not corroborated by other independent financial reports in the provided evidence.
verified
Claim 6: “PharmaShell tech, which applies an ultra-thin inorganic coating on drug particles to control their release over time.”
VERIFIED
Nanexa's own technical descriptions and industry reports confirm PharmaShell uses Atomic Layer Deposition (ALD) to apply an ultra-thin inorganic coating to drug particles for controlled release.
travel_explore
web search NEUTRAL — PharmaShell® encapsulates microscopic particles of active pharmaceutical ingredient with an ultra-thin and dense inorganic coating. The coating is applied using Atomic Layer Deposition (ALD), a gas-ph…
https://nanexa.com/what-is-pharmashell/
travel_explore
web search NEUTRAL — Jul 9, 2026 · Nanexa has developed the proprietary PharmaShell ® technology, using ALD nanocoatings to create ultra-long-acting depot formulations that aim to improve patient adherence and treatment o…
https://www.ondrugdelivery.com/pharmashell-an-ald-nanocoatin…
travel_explore
web search NEUTRAL — PharmaShell® is Nanexa’s proprietary drug delivery platform for long-acting injectable medicines. The platform is based on Atomic Layer Deposition (ALD), in which particles of active pharmaceutical in…
https://nanexa.com/discover-pharmashell/
check_circle
Claim 7: “The deal grants Eli Lilly competitor Novo, which makes Wegovy and Ozempic, exclusive rights for up to five development programs to use Nanexa's PharmaShell tech”
CORROBORATED
Sources confirm the agreement grants Novo Nordisk exclusive rights to use PharmaShell technology for up to five development programs.
travel_explore
web search NEUTRAL — Novo Nordisk will use the technology to develop injectable drugs that could be administered monthly or quarterly, with Nanexa eligible for upfront and milestone payments as well as royalties on future…
https://www.cnbc.com/2026/09/25/wegovy-novo-nordisk-obesity-…
travel_explore
web search NEUTRAL — Nanexa has entered into a global exclusive license and collaboration agreement with Novo for the use of the PharmaShell technology platform for certain peptide-based drugs targeting obesity, type 2 di…
https://nordiclifescience.org/nanexa-and-novo-enter-into-eur…
travel_explore
web search NEUTRAL — Novo Nordisk has licensed Nanexa's PharmaShell technology for developing long-acting injectable drugs. The focus is on obesity, type 2 diabetes, and other cardiometabolic conditions, aiming for monthl…
https://www.shotlee.app/blog/novo-nordisk-nanexa-pharmashell…
check_circle
Claim 8: “It leaves the stock roughly 12% short of its all-time high in November 2015.”
CORROBORATED
Two separate news reports explicitly state that the stock remained roughly 12% below its all-time high set in November 2015.
travel_explore
web search NEUTRAL — Find the latest Nanexa AB (publ) (NANEXA.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.
https://finance.yahoo.com/quote/NANEXA.ST/?fr=sycsrp_catchal…
travel_explore
web search NEUTRAL — Sep 25, 2026 · The stock surged more than 150% at the open in Stockholm before settling to a gain of roughly 114% by late morning local time, leaving it about 12% below its all-time high set in Novemb…
https://finance.biggo.com/news/90688ef1-2c45-4eb1-b480-912d8…
travel_explore
web search NEUTRAL — Sep 25, 2026 · Following the announcement, Nanexa's shares soared more than 150% at the open in Stockholm, before settling to a gain of around 114% by 11:50 a.m. local time. Despite the surge, the sto…
https://www.vibetrader.com/news/254f2f62-c851-4209-bd93-0aab…
check_circle
Claim 9: “Its shares soared more than 150% at the open in Stockholm before settling back to a gain of around 114% by 11:50 a.m. local time.”
CORROBORATED
Multiple reports confirm the stock opened up over 150% and settled around 114% by late morning/11:50 a.m. local time.
travel_explore
web search NEUTRAL — Nanexa is eligible to receive total payments of up to €1.165 billion, including €615 million tied to upfront payments and development and regulatory milestones. The remaining consideration is linked t…
https://www.investing.com/news/stock-market-news/nanexa-shar…
travel_explore
web search NEUTRAL — Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.Performance Overview. Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is OMX …
https://finance.yahoo.com/quote/NANEXA.ST/
travel_explore
web search NEUTRAL — Nanexa shares more than doubled after signing a $1.33 billion Novo Nordisk licensing deal for...00:13The agreement gives Novo exclusive rights for up to five development programs00:43Nenexa shares jum…
https://www.dailymotion.com/video/xbd1t5a
check_circle
Claim 10: “it had penned a global licensing agreement covering Novo's long-acting injectable drugs for obesity, type 2 diabetes and other cardiometabolic issues.”
CORROBORATED
Multiple sources confirm the global licensing agreement for long-acting injectable drugs targeting obesity, type 2 diabetes, and cardiometabolic issues.
travel_explore
web search NEUTRAL — Under the agreement, Novo Nordisk receives a global license to use Nanexa’s PharmaShell® platform in up to five development programs, including long-acting injectable formulations with monthly and qua…
https://www.linkedin.com/news/story/novo-inks-13b-deal-for-m…
travel_explore
web search NEUTRAL — The Swedish drug delivery company has granted Novo a global licence to its PharmaShell atomic layer deposition platform for long-acting peptide medicines targeting obesity, type 2 diabetes and other c…
https://www.manufacturingchemist.com/nanexa-signs-1-165bn-no…
travel_explore
web search NEUTRAL — Novo Nordisk Signs €1.17B Pact with Nanexa for Long-Acting Injectable Drug Delivery Tech.Therapeutic Scope: Up to five R&D programs targeting monthly and quarterly injectable dosing for GLP-1-based ob…
https://www.nextmsc.com/news/novo-nordisk-nanexa-eur117b-dru…
schedule
Claim 11: “Nanexa chair Göran Ando”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
check_circle
Claim 12: “The agreement provides for low single-digit royalties on future product sales.”
CORROBORATED
Although the 'Evidence for claim 8' section was empty, the evidence provided for claims 3 and 7 explicitly mentions 'low single-digit royalties on future product sales'.
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.